survey men

Clinical studies/trials are important in finding more and better treatments. Participation in clinical studies or trials offers one way to help advance research into gastrointestinal (GI) disorders. Here is a list of clinical studies, in adults and children, that are seeking participants. A description of the study purpose and contact information is included.

 

All Functional GI Disorders

ClinTrial 1 12

Purpose of study: Researchers at the NIH are seeking healthy volunteers for a study looking at how common antibiotics change the human microbiome. The microbiome is a collection of tiny organisms that live in and on our bodies. Changes in the microbiome may affected immune function, metabolism, and other aspects of health and disease.

Sponsor: National Institutes of Health (NIH) 

Participation: Non-smokers between the ages of 21-39 years with no chronic medical conditions are invited to participate

About the study: During this study, participants may:

  • Receive one course of either amoxicillin, azithromycin, or no antibiotic.
  • Provide blood, urine, feces, saliva, skin, and vaginal swab samples before, during, and after treatment.
  • Have about 11 outpatient visits over one year.
  • Participate in an optional sub study that includes three overnight stays in an environmentally controlled room that measures how your body uses energy.

Compensation for participation is provided.

Contact: For more information, visit www.clinicalstudies.info.nih.gov or call the NIH Clinical Center Office of Patient Recruitment at 1-866-444-1132 (TTY: 1-866-411-1010) and refer to the study number #16-I-0078..

Added December 2018

 

Online Registry of Individuals with a Functional GI Disorder 

Purpose of study: Participants sought for inclusion in a registry of individuals with functional GI disorders, in order to acquire a pool of individuals for contact for future studies.

Sponsor: Macquarie University, Australia

Participation: Any individual with a functional GI disorder and some level of abdominal discomfort is invited to participate.

About the study: Individuals included in the registry may be invited to participate in future research studies conducted by online questionnaire.

Contact: For more information, visit www.mqedu.qualtrics.com or This email address is being protected from spambots. You need JavaScript enabled to view it..

Verified August 2017

Top of Page

 

Gastroesophageal Reflux Disease (GERD)

ClinTrial 2

Purpose of study: The purpose of this study is to evaluate the safety and efficacy of IW-3718 administered to patients who continue to have persistent symptoms of gastroesophageal reflux disease (GERD), such as heartburn and regurgitation, while receiving once-daily (QD), standard-dose proton pump inhibitors (PPIs).

Sponsor: Ironwood Pharmaceuticals, Inc.

Participation: Adult patients ages 18 and older with a diagnosis of GERD and reporting persistent GERD symptoms (heartburn or regurgitation) while taking standard PPI therapy. Eligible volunteers will be given three tablets twice daily, immediately after the morning and evening meals.

79 US study locations are enrolling for this study.

Contact: For more information, visit the study listing on clinicaltrials.gov.

Added December 2018

ClinTrial 2

Purpose of study: The purpose of this study is to evaluate the safety and efficacy of IW-3718 administered to patients who continue to have persistent symptoms of gastroesophageal reflux disease (GERD), such as heartburn and regurgitation, while receiving once-daily (QD), standard-dose proton pump inhibitors (PPIs).

Sponsor: Ironwood Pharmaceuticals, Inc.

Participation: Adult patients ages 18 and older with a diagnosis of GERD and reporting persistent GERD symptoms (heartburn or regurgitation) while taking standard PPI therapy. Eligible volunteers will be given three tablets twice daily, immediately after the morning and evening meals.

82 US study locations are enrolling for this study.

Contact: For more information, visit the study listing on clinicaltrials.gov.

Added December 2018

 

Gastroparesis

ClinTrial 1 17

Purpose of study: Primary Objective: To assess the efficacy of treatment with various dose levels of TAK-906 in adult subjects with gastroparesis compared with placebo during 12 weeks of treatment. Secondary Objectives: To evaluate the safety and tolerability of TAK-906 doses compared with placebo during 12 weeks of treatment.

Additional Objectives: • To evaluate the pharmacokinetics of TAK-906 in subjects with gastroparesis • To evaluate the effect of TAK-906 on quality of life compared with placebo. • To evaluate the potential relationship between changes in C-reactive protein (CRP), glucose-dependent insulinotropic peptide (GIP), peptide tyrosine tyrosine (PYY), clinical symptoms and motility response • To evaluate the effect of TAK-906 on GEBT.

Sponsors: Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited

Participation: Main Criteria for Inclusion:  Subject eligibility is determined according to the following criteria before entry into the study: • Adult men and women aged 18 to 85 years, inclusive, and with body mass index ≥19 to ≤40 kg/m2 inclusive. • Subjects should have symptoms of gastroparesis (eg, postprandial fullness, nausea, vomiting, upper abdominal pain, and early satiety) for at least 3 months before Screening as assessed by a physician.  • Subjects must have an average composite ANMS GCSI-DD symptom score ≥2 during the 7 days before randomization. The predominant symptom experienced by subjects must not be abdominal pain. • Subjects must experience nausea: nausea subscale (of ANMS GCSI-DD) symptom score ≥2 at least 4 of 7 days or an average nausea subscale symptom score ≥2 during the 7 days before randomization. Nausea symptoms must not be attributable to a central disorder (eg, motion sickness, glaucoma, menstrual cycles, migraine headache). • Subjects must have confirmed delayed gastric emptying at Screening: delayed gastric emptying by GEBT, defined as time to gastric half emptying (t1/2) ≥79 minutes (80th percentile). • Absence of gastric outlet obstruction confirmed by upper GI, CT, or endoscopy. Special Inclusion for Subjects with Diabetes Mellitus • Subjects must have glycosylated hemoglobin (HbA1c) ≤11% before the Randomization Visit. 

Contacts: Peter L. Moses, MD Phone: 617-444-1309, Email: This email address is being protected from spambots. You need JavaScript enabled to view it.. For more information, visit the study listing on clinicaltrials.gov.

Added January 2019

ClinTrial 1 20

Purpose of study: To study an investigational drug to help symptoms for Diabetic Gastroparesis. 

Sponsors: UNC Center for Esophageal Diseases and Swallowing.

Participation: Do you have Diabetic Gastroparesis? (i.e. : nausea, abdominal pain, post-prandial fullness, bloating, vomiting, and early satiety) If you are at least 18 years of age and currently suffering from symptoms of Diabetic Gastroparesis, you may be eligible for a research study involving an investigational drug to help reduce these symptoms. Study participation could last as long as 12-weeks. Compensation may be included for eligible participants.

Contacts: If you are interested in learning more about this study, please call (919) 843-0821 or email This email address is being protected from spambots. You need JavaScript enabled to view it.

Added January 2019

Top of Page

 

Rare Genetic Diseases

Recruiting Individuals with Rare Genetic Disorders

Purpose of study: In an effort to help researchers working to understand gastrointestinal motility diseases like mitochondrial nueorgastrointestinal encephalopathy, blood samples and clinical data from individuals with rare genetic diseases are being collected. The samples are made anonymous and shared with scientists to use in their research for treatments and causes. Families living outside the US are also welcome to donate a sample to the repository.

Sponsors: The National Institute of General Medical Sciences (NIGMS) Human Genetic Cell Repository Program and Coriell Institute for Medical Research

Participation: Eligible individuals with an inherited genetic disease or chromosomal abnormality

Contacts: Families who want to participate in this research effort can can read more about the Repository and donation process here, or can contact the NIGMS Human Genetic Cell Repository genetic counselor, Tara Schmidlen, MS, CGC, for postage-paid sample collection kits and the necessary paperwork: Phone: 856-757-4822, Email: This email address is being protected from spambots. You need JavaScript enabled to view it..

Verified August 2017

Top of Page

 

Pediatric Gastrointestinal Disorders

ClinTrial 1 21

Purpose of study: The purpose of this study is to evaluate the safety and efficacy of linaclotide for the treatment of irritable bowel syndrome with constipation (IBS-C) in children ages 7 to 17 years.

Sponsor: Forest Laboratories; Ironwood Pharmaceuticals, Inc.

Participation: Children ages 7-17 years meeting Rome III criteria for IBS and functional constipation (lat least once per week for at least 2 months before the screening visit, the child must experience abdominal discomfort or pain associated with 2 or more of the following: 

  • Improvement with defecation
  • Onset associated with a change in frequency of stool
  • Onset associated with a change in form (appearance) of stool

Eligible volunteers will receive various doses of linaclotide or placebo during a 4-week study. Patients ages 7-11 years will receive liquid oral solution or solid capsules while ages 12-17 years will only receive solid oral capsules.

79 US study locations are enrolling for this trial.

Contact: For more information, visit the study listing on clinicaltrials.gov.

Added December 2018

ClinTrial 1 22

Purpose of study: The purpose of this research study is to learn more about the relationship between children's bowel habits and the way they react to sensory input. Some children are very sensitive to the way things feel, smell, and sound, and this might interfere with their willingness to use the toilet for a bowel movement. Eligible participants will be asked to complete 4 questionnaires with questions related to these reactions to sensation and bowel habits of children.

Sponsor: University of Newcastle

Participation: Parents of children between ages 3 and 6 years. The study will include children with or without functional defecation issues who may or may not also have a diagnosis of ADHD or autism. Excluded from the study are children with organic defecation issues and/or a diagnosis other than ADHA or autism. 

Contact: Enter your information on this online contact form to receive additional study information or contact Isabelle Beaudry-Bellefeuille at This email address is being protected from spambots. You need JavaScript enabled to view it.

Added August 2017

Celiac Disease

Participants Needed for POWER-C Study

Purpose of study: The POWER-C (Promotion of Optimal Well-Being, Education, and Regulation for Celiac Disease) study is a free online, evidence-based program for people newly diagnosed and/or struggling with celiac disease. The purpose of the study is to examine the impact of an 8-week online program containing 4 modules to be completed bi-weekly in adults with celiac disease. Participants will be asked to complete online questionnaires at 4 time points.

Sponsor: University of Calgary

Participation: Adult individuals (ages 18+) located in North America diagnosed with celiac disease (blood test and/or biopsy). Eligible individuals are required to follow a strict gluten-free diet to participate.

Contact: Dr. Justine Dowd. Phone: 1-403-210-8482. Email: This email address is being protected from spambots. You need JavaScript enabled to view it.. For additional information: www.cureceliacdisease.org/wp-content/uploads/power_c.pdf.

Verified May 2018

Chronic Intestinal Pseudo-Obstruction

Diagnostic Gene Studies for Chronic Intestinal Pseudo-Obstruction

A mutation in a gene transmitted through a dominant mode of inheritance (an affected person having a 50% risk of passing the disorder to each of his or her children) can cause chronic intestinal pseudo-obstruction (CIPO), with or without frequent bladder involvement. The disorder can also occur due to a new mutation. Thus far, the most important gene discovered with mutations is the ACTG2 gene.

A second gene is being sought by the Center for Human Genetics. Families who wish to participate in this research effort can email Aubrey Milunsky, MD at This email address is being protected from spambots. You need JavaScript enabled to view it. for details.

Verified May 2018

Irritable Bowel Syndrome (IBS)

ClinTrial 1 23

Purpose of study: The objective of this study is to determine the effect of linaclotide on abdominal girth in participants with irritable bowel syndrome with constipation (IBS-C) with the baseline symptoms of abdominal bloating and an increased abdominal girth. 

Sponsor: Ironwood Pharmaceuticals, Inc. 

Participation: 18 years or older diagnosed with IBS-C, abdominal pain, abdominal bloating and abdominal girth. 

Contact: Ironwood Pharmaceuticals +1 (617)621-8394. 

Refer to this study by its ClinicalTrials.gov identifier NC102837783.

Added August, 2018

ClinTrial 1 24

Purpose of study: This study involves free nutrition sessions with a skilled IBS-specializing dietitian.

Sponsor: UCLA Oppenheimer Family Center for Neurobiology of Stress

Participation: Eligible male and female individuals ages 18 and older with a diagnosis of IBS with diarrhea or diarrhea with constipation (IBS-D or IBS-M). To participate, individuals must not have tried the low FODMAP diet before.

Contact: For more information, visit www.uclacns.org/patients/clinical-research or call (310) 206-1656. You may also email Nafessa Islam at This email address is being protected from spambots. You need JavaScript enabled to view it..

Verified May 2018

ClinTrial 1 25

Purpose of study: The purpose of this study is to examine brain networks at rest in chronic pain conditions compared to healthy controls.

Sponsor: UCLA Oppenheimer Family Center for Neurobiology of Stress

Participation: Men and women between the ages of 18 and 55 who are diagnosed with IBS, right handed, not pregnant and no significant neurological or psychological medical history.

About the study: Participation involves a screening visit, an MRI and one stool sample.

Participants will be compensated up to $100 and get a digital picture of your brain.

Contact: For more information, visit www.uclacns.org/patients/clinical-research or call (310) 206-8545. You can also email Nafeesa Islam at This email address is being protected from spambots. You need JavaScript enabled to view it..

Added May 2018

ClinTrial 1 26

Purpose of study: To provide treatment to patients with IBS-D.

Sponsor: University of Michigan and Michigan Institute for Clinical and Health Research (MICHR)

Participation: Men and women over the age of 18 diagnosed with IBS-D. Prior colonoscopy or sigmoidoscopy within the past 2 years with random colon biopsies to exclude the presence of microscopic colitis.

About the study: Patients will receive either rifaximin or low FODMAP dietary intervention.

Contact: For more information, visit https://clinicaltrials.gov/ct2/ or contact Dr. Allen Lee at (734) 936-9454, This email address is being protected from spambots. You need JavaScript enabled to view it..

Added May 2018

 

Participants Sought for Study on Complementary Approaches to the Treatment of IBS

Purpose of study: The purpose of this study is to find a complementary treatment to help Irritable Bowel Syndrome (IBS) patients in need of relief.

About The Study: The length of this study will be three weeks long, with a short online intervention everyday to help individuals deal with their body’s reactions to their environments. Participants will have additional surveys to assess their overall state at the beginning of the study, at the end of the three week intervention, and again at six weeks for a follow-up.

Participation: Eligible individuals between the ages of 18 – 65 years of age who are experiencing pain or discomfort associated with their gut. Cannot be smokers or have an inflammatory bowel disease.

How to Sign Up: http://bit.ly/IBS_study

There will be a $15 Target gift card for first 30 participants upon completion of study.

Study Contact: Jenna N. Ray,  Health Psychologist. Phone: (919) 257 – 7291, Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Verified August 2017

ClinTrial 1 27

Purpose of study:  This online survey has been constructed in order to compile written reports of IBS episodes and help the researchers gain a better understanding of the symptoms and experiences people have during an IBS episode.

About the study: Have you been diagnosed with IBS? If so, you are eligible to help out with a one-time online survey that may take up to 20 minutes to complete. This survey is completely confidential and you will not be asked any identifying information.

Sponsor: University of North Carolina – Chapel Hill and the Drossman Center for Education and Practice of Biopsychosocial Care

To participate: Click here to begin.

Study Contact: Dr. Stephan Weinland. Phone: (919) 843 – 4422, Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Verified August 2017 

 

Online Survey on Symptoms in IBS

Purpose of study:  One of the most important questions for individual patients with irritable bowel syndrome (IBS) is how long the symptoms will continue. A number of factors are thought to be important in determining recovery from IBS but so far studies have not been big enough to be certain of the results. The aim of this world-wide survey will be to gather together the experience of a large number of patients with irritable bowel syndrome, both those in whom it has begun with an infection and those in whom it has not. By comparing these we will be able to understand more about both conditions.

About the study: This is a web-based survey designed to help learn more about irritable bowel syndrome in order that physicians might better plan treatments and management. Of particular interest is how symptoms develop over time. The study is multilingual and is currently available in nine languages.

Sponsor: European Gastroenterology Federation

To participate: Go to www.postinfectious-ibs.eu and click on your language of choice to complete the simple online questionnaire.

Verified August 2017  

 

 

Accidental Bowel Leakage (or Incontinence)

ClinTrial 1 42

Purpose of study: This 12 week Phase III study will assess the efficacy and safety of a combination clonidine and colesevelam compared with placebo in women with diarrhea and urge predominant fecal incontinence.

Sponsor: NIH and Mayo Clinic

Participation: Women aged 18 to 80 years of age with diarrhea and urge predominant or combination (urge and passive) fecal incontinence for at least one year duration.

ContactKelly Feuerhak (email: This email address is being protected from spambots. You need JavaScript enabled to view it. or phone: 507-255-6802), Subhankar Chakraborty (email: This email address is being protected from spambots. You need JavaScript enabled to view it. or phone: 507-255-4803), or Adil Bharucha (email: This email address is being protected from spambots. You need JavaScript enabled to view it. or phone: 507-284-2687). Refer to this study by its ClinicalTrials.gov identifier NCT02628262

Verified August 2017

ClinTrial 1 36

Purpose of study: Compare the treatment response with a low FODMAP vs. psyllium based on number of episodes in patients with FI and the efficacy of a low FODMAP diet vs. psyllium in patients with FI on pre-specified clinical and quality of life endpoints.

SponsorUniversity of Michigan 

Participation: Men and women between the ages of 18 and 90, experience at least 1 episode/week of unintentional loss of stool associated with diarrhea/loose stool (Bristol stool scale of 5 or greater) and meet the Rome III criteria for Functional Fecal incontinence diagnostic criteria.

Contact: Stacy Menees, MD734-936-6400, This email address is being protected from spambots. You need JavaScript enabled to view it..

Refer to this study by its ClinicalTrials.gov identifier NCT02828384.

Added May 2018

ClinTrial 1 38

Purpose of study: The UNC Center for Functional GI & Motility Disorders is in the process of validating a symptom diary that will be used in a future research study. The aim of this portion of the study is to determine if people who do and do not have accidental bowel leakage, also known as fecal incontinence, understand the diary questions and can provide feedback on the diary.

Participation in this research study will involve filling out a daily diary for four weeks and answering questionnaires before and after the research study. This research study will involve two in-person visits that will last up to 60 minutes each.

Participants can earn up to $100 for participation in this research study.

Sponsor: UNC Center for Functional GI & Motility Disorders

Participation: Individuals both with and without fecal incontinence.

Contact: Stefanie Twist (email: This email address is being protected from spambots. You need JavaScript enabled to view it.or phone: 919-843-6961)

Verified May 2018

Gulf War Multisymptom Illness

ClinTrial 1 39

Purpose of research: The onset of certain gastrointestinal (GI) disorders, including irritable bowel syndrome (IBS), functional dyspepsia, and chronic abdominal pain syndrome, can be triggered by severe stress and infections of the digestive tract. Deployed military personnel face an elevated chance of experiencing these risk factors and developing a disorder as a result of their service. A prominent condition affecting Veterans of the Gulf War theater of operations is a cluster of medically unexplained chronic symptoms. Collectively, these are referred to as "multisymptom illness."

The War Related Illness and Injury Study Center (WRIISC) regularly conducts research into these illnesses to understand the underlying mechanisms and develop treatments to help manage symptoms. 

Sponsor: US Department of Veterans Affairs (VA) 

Participation: Veterans of active service in the Gulf War theater of operations.

Contact: For more information or to participate go to www.warrelatedillness.va.gov. 

Added March 2018

Colorectal Cancer

Seeking Participants with History of Cancer to Participate in Lifestyle and Quality of Life Study

Purpose of study: The goal of this anonymous online survey study is to gain a better understanding of how to support quality of life in cancer. The survey will include questions on lifestyle, demographics, health history, physical and psychological functioning, and healthcare preferences. The survey will take approximately 10 minutes to complete.

Sponsor: Tulane University 

Participation: Adults ages 18 and older with a past or present cancer diagnosis.

Contact: For more information or to participate go to www.tulanestudy.com/ or contact Laura Perry (email: This email address is being protected from spambots. You need JavaScript enabled to view it.). 

Added August 2017

Seeking Women who are Breast Feeding or Pumping and are Taking Linaclotide for IBS-C or CIC 

Purpose of study: This study will determine the amount of linaclotide in breast milk after once daily doses of the drug over 4 consecutive days.

Sponsor: Forest Laboratories

Participation: Eligible female patients currently taking linaclotide for constipation predominant irritable bowel syndrome (IBS-C) or chronic idiopathic constipation (CIC) who have been actively breastfeeding or pumping for at least 4 weeks.

Phase: Phase 1

Location: Iowa City, Iowa

Contacts: Sandra Beaird, Pharm.D. Phone: 1-800-678-1605, ext 66297; Be sure to refer to this study by its ClinicalTrials.gov identifier: NCT02220348

Verified May 2018

Short Bowel Syndrome (SBS)

ClinTrial 1 41

Purpose of study: Registry to evaluate the long-term safety profile for patients with SBS who are treated with teduglutide in a routine clinical setting. 

Sponsor: Shire

Participation: SBS patients treated and not treated with teduglutide will be enrolled. All ages accepted. This is an observational study. Data will be collected during routine consultations and clinical staff will enter this information into a system baseline and approximately every 6 months following. Each patient will be followed for at least 10 years.

Contact: Shire contact This email address is being protected from spambots. You need JavaScript enabled to view it.. ClinicalTrials.gov identifier: NCT01990040

Added July 2018

Study of Oral AK002 in Patients with Eosinophilic Gastritis with or without Eosinophilic Gastroenteritis

Purpose of Study:A randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, tolerability, and pharmacodynamic effect of AK002 in patients with eosinophilic gastritis with or without eosinophilic gastroenteritis. 

Sponsor: Allakos, Inc. 

Participation: Ages 18 years and up, symptoms of EG and/or EGE (abdominal pain, diarrhea, and/or nausea); eosinophiliaof the gastric and/or duodenal mucosae.

About the study: This is a phase 2, randomized, double-blind, placebo-controlled study to assess the effects of AK002, given monthly for 4 doses. Open-labeled long-term continuation treatment will be available upon completion of the study. It is hypothesized that AK002 is more effective than placebo control in reducing the number of eosinophilis in gastric and duodenal biopsies. 

Contact: Henry Rasmussen MD, PhD 443-699-5230 or This email address is being protected from spambots. You need JavaScript enabled to view it.. be sure to refer to this study by its ClinicalTrials.gov identifier: NCT03496571

Added October 2018

 

What are Phases?

Research Awards
2018 Award Recipients
Amaranath Karunanayake, PhD
Katja Kovacic, MD
Cristina Martinez, PhD
Ans Pauwels, PhD
2013 Award Recipients
Enrico Corazziari, MD
Jan Tack, MD, PhD
Report from Gary Mawe, PhD: The Roles of Intestinal Nerves and Serotonin in Gut Function and Dysfunction
Ashley Blackshaw, PhD
Carlo Di Lorenzo, MD
Niranga Manjuri Devanarayana, MD
Report from Lukas Van Oudenhove, PhD: Solving the Biopsychosocial Puzzle in Functional Dyspepsia
Muriel Larauche, PhD
2011 Award Recipients
Report from Ronnie Fass, MD: Sleep and Gastroesophageal Reflux Disease (GERD)
Million Mulugeta, PhD
Adrian Miranda, MD
Samuel Nurko, MD
Sudarshan Jadcherla, MD
Shaman Rajindrajith, MD
2009 Award Recipients
Satish Rao, MD
Emeran Mayer, MD
Javier Santos, MD
Report from Martin Storr, MD, PhD: Functional Gastrointestinal Disorders: New Insights in Enteric Regulation
Report From Miguel Saps, MD: Functional Abdominal Pain in Children and Adolescents
2007 Award Recipients
Report from Bruce D. Naliboff, PhD: Symptom Based Psychology for Functional Gastrointestinal Disorders
Report from Magnus Simrén, MD, PhD: Irritable Bowel Syndrome: Searching for Underlying Causes
Report from Brennan M. R. Spiegel, MD, MSHS: Diagnostic Testing in Irritable Bowel Syndrome: Theory vs. Reality
Report from Sylvie Bradesi, PhD: Role of the Central Immune System in Functional Disorders
Paul E. Hyman, MD
Report from Miranda A. L. van Tilburg, PhD: Home Based Guided Imagery to Treat Pediatric Functional Abdominal Pain
Report from Fernando Azpiroz, MD, PhD: Understanding Intestinal Gas
2005 Award Recipients
Report from Yvette Tache, PhD: Stress and Irritable Bowel Syndrome: Unraveling the Code
Report from Shaheen Hamdy, MRCP, PhD: Adult Neurogenic Dysphagia -- Disorders and Conditions that Disrupt Swallowing
Report from Michael A. Pezzone, MD, PhD: Chronic Pelvic Pain and the Overlap of Pelvic Pain Disorders
Report from Bridget R. Southwell, PhD: Research into Treatment-Resistant Constipation in Children
Report from Rachel Rosen, MD, MPH: Symptoms Arising from Non-Acid Reflux in Children
2003 Award Recipients
Report from William E. Whitehead, PhD: Summary of Clinical Research Activities
Jyoti N. Sengupta, PhD
Report from Caroline Elder Danda, PhD: Biopsychosocial Perspectives on Assessment and Treatment
Report from Terry Buchmiller-Crair, MD: Using the Fetal Gastrointestinal Tract to Overcome Neonatal Disease
Report from Dan L. Dumitrascu, MD, PhD: The Psychosocial Adjustment to Illness in Irritable Bowel Syndrome
Report from Klaus Bielefeldt, MD, PhD: Understanding Pain and Discomfort in Functional GI Disorders
Research Grants
IFFGD Competitive Grants
2014 IFFGD Idiopathic Gastroparesis Research Grants
Leo Cheng, PhD
Braden Kuo, MD, MSc
Richard McCallum, MD
2008 IFFGD Competitive Research Grants
IFFGD Noncompetitive Grants
Other Research Grant Opportunities
Funding Research
Need for Funding Research
How to Make a Difference
The State of Research at NIH & NIDDK
Clinical Trials & Studies
Guide to Randomized Clinical Trials
Clinical Trials and Studies

Funding Research

IFFGD2018Breakfast 002 cropped

IFFGD funds research that helps to shape science and scientific advancement, and improve quality of life for people affected by chronic digestive disorders.

IFFGD Research Awards

Professional Education

Research funding needs 

Give Today

give today

Your GIFT can change a life

Your donations help to fund life-changing research and education about chronic digestive conditions and the critical need for improved treatments.

Together, we make a difference.

Donate online